The 25th anniversary of the Eurotransplant Acceptable Mismatch program for highly sensitized patients

Hendriks, 1985, Eurotransplant experience with highly immunized patients, Scand. J. Urol. Nephrol. Suppl., 92, 81 Doxiadis, 2005, Extending options for highly sensitized patients to receive a suitable kidney graft, Curr. Opin. Immunol., 17, 536, 10.1016/j.coi.2005.07.010 Kissmeyer-Nielsen, 1966, Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells, Lancet, 24, 662, 10.1016/S0140-6736(66)92829-7 Patel, 1969, Significance of the positive crossmatch test in kidney transplantation, N. Engl. J. Med., 280, 735, 10.1056/NEJM196904032801401 Gebel, 2003, Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk, Am. J. Transplant., 3, 1488, 10.1046/j.1600-6135.2003.00273.x Claas, 1988, A special strategy to increase the chance of finding cross-match negative kidneys for highly sensitized patients, Transplant. Proc., 20, 947 Claas, 1988, The hyperimmunized patient: from sensitization toward transplantation, Transpl. Int., 1, 53, 10.1007/BF00353819 Claas, 1989, Transplantation of highly sensitized patients on the basis of acceptable HLA-A and B mismatches, Clin. Transpl., 185 Claas, 1989, Hyperimmunized patients do not need to wait for an HLA identical donor, Tissue Antigens, 34, 23, 10.1111/j.1399-0039.1989.tb01713.x Claas, 1988, Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life, Science, 241, 1815, 10.1126/science.3051377 van Rood, 1967, A proposal for international cooperation in organ transplantation: Eurotransplant, 451 Claas, 2009, Management of the highly sensitized patient, Curr. Opin. Immunol., 21, 569, 10.1016/j.coi.2009.07.010 Schwartz, 1980, HLA serological cross-reactivity: HLA-B15 has two public antigens, Hum. Immunol., 1, 331, 10.1016/0198-8859(80)90109-3 Schwartz, 1980, A public antigenic determinant in the HLA-B5 cross-reacting group—a basis for cross-reactivity and a possible link with Behcet's disease, Hum. Immunol., 1, 37, 10.1016/0198-8859(80)90008-7 Fuller, 1990, Topographic map of the HLA-A2 CREG epitopes using human alloantibody probes, Hum. Immunol., 28, 284, 10.1016/0198-8859(90)90058-W Fuller, 1990, Epitope map of the HLA-B7 CREG using affinity-purified human alloantibody probes, Hum. Immunol., 28, 306, 10.1016/0198-8859(90)90059-X Papassavas, 2000, Epitope analysis of HLA class I donor specific antibodies in sensitized renal transplant recipients, Transplantation, 70, 323, 10.1097/00007890-200007270-00016 Doxiadis, 1996, Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept, Lancet, 348, 850, 10.1016/S0140-6736(96)02296-9 Rodey, 1987, Public epitopes and the antigenic structure of the HLA molecules, Crit. Rev. Immunol., 7, 229 Tambur, 2015, HLA epitopes as viewed by antibodies: what is it all about?, Am. J. Transplant., 15, 1148, 10.1111/ajt.13192 Claas, 2006, Differential immunogenicity of HLA class I alloantigens for the humoral versus the cellular immune response: “towards tailor-made HLA mismatching”, Hum. Immunol., 67, 424, 10.1016/j.humimm.2006.03.004 Claas, 2005, Differential immunogenicity of HLA mismatches in clinical transplantation, Transpl. Immunol., 14, 187, 10.1016/j.trim.2005.03.007 Duquesnoy, 2002, HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes, Hum. Immunol., 63, 353, 10.1016/S0198-8859(02)00381-6 Duquesnoy, 2002, HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm, Hum. Immunol., 63, 339, 10.1016/S0198-8859(02)00382-8 Claas, 2004, The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome, Transplantation, 78, 190, 10.1097/01.TP.0000129260.86766.67 Dankers, 2004, The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens, Transplantation, 77, 1236, 10.1097/01.TP.0000120385.03278.28 Duquesnoy, 2003, HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. IV. An alternative strategy to increase the number of compatible donors for highly sensitized patients, Transplantation, 75, 889, 10.1097/01.TP.0000055097.58209.83 Duquesnoy, 2003, HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A, B amino acid triplet level on kidney transplant survival, Transplantation, 75, 884, 10.1097/01.TP.0000055101.20821.AC Duquesnoy, 2004, HLAMatchmaker-based strategy to identify acceptable HLA class I mismatches for highly sensitized kidney transplant candidates, Transpl. Int., 17, 22, 10.1111/j.1432-2277.2004.tb00379.x Claas, 2009, Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program, Transplantation, 88, 447, 10.1097/TP.0b013e3181b04a5f Duquesnoy, 2007, HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP, Hum. Immunol., 68, 12, 10.1016/j.humimm.2006.10.003 Wiebe, 2013, Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes, Am. J. Transplant., 13, 3114, 10.1111/ajt.12478 Duquesnoy, 2006, A structurally based approach to determine HLA compatibility at the humoral immune level, Hum. Immunol., 67, 847, 10.1016/j.humimm.2006.08.001 Kosmoliaptsis, 2008, Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker, Transplantation, 85, 1817, 10.1097/TP.0b013e31817441d6 Loupy, 2013, Complement-binding anti-HLA antibodies and kidney-allograft survival, N. Engl. J. Med., 369, 1215, 10.1056/NEJMoa1302506 Amico, 2011, Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations, Transpl. Int., 24, 560, 10.1111/j.1432-2277.2011.01235.x Broers, 2015, Quality of life in dialysis patients: a retrospective cohort study, Nephron, 130, 105, 10.1159/000430814 van den Berg-Loonen, 2008, Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients, Transplantation, 85, 1086, 10.1097/TP.0b013e31816b3ed1 Doxiadis, 2000, The relevance of proficiency testing for laboratories involved in cadaveric organ transplantation and its consequences for graft survival, Clin. Transpl., 99 Bielmann, 2007, Pretransplant risk assessment in renal allograft recipients using virtual crossmatching, Am. J. Transplant., 7, 626, 10.1111/j.1600-6143.2007.01667.x Zachary, 2009, Using real data for a virtual crossmatch, Hum. Immunol., 70, 574, 10.1016/j.humimm.2009.06.007 Morris, 2010, Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation, Hum. Immunol., 71, 268, 10.1016/j.humimm.2010.01.003 Duquesnoy, 2013, 16th IHIW: a website for antibody-defined HLA epitope registry, Int. J. Immunogenet., 40, 54 Duquesnoy, 2014, First report on the antibody verification of HLA-ABC epitopes recorded in the website-based HLA Epitope Registry, Tissue Antigens, 83, 391, 10.1111/tan.12341 Duquesnoy, 2014, First report on the antibody verification of HLA-DR, HLA-DQ and HLA-DP epitopes recorded in the HLA Epitope Registry, Hum. Immunol., 75, 1097, 10.1016/j.humimm.2014.09.012 Duquesnoy, 2007, 14th International HLA and Immunogenetics Workshop: report on the structural basis of HLA compatibility, Tissue Antigens, 69, 180, 10.1111/j.1399-0039.2006.00766.x Tambur, 2014, Epitope analysis of HLA-DQ antigens: what does the antibody see?, Transplantation, 98, 157, 10.1097/TP.0000000000000220 Kosmoliaptsis, 2009, Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms, Transplantation, 88, 791, 10.1097/TP.0b013e3181b4a9ff Kosmoliaptsis, 2011, High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes, Hum. Immunol., 72, 1049, 10.1016/j.humimm.2011.07.303 Kosmoliaptsis, 2011, Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms, Transplantation, 91, 183, 10.1097/TP.0b013e3181ffff99 Mallon, 2015, Three-dimensional structural modelling and calculation of electrostatic potentials of HLA Bw4 and Bw6 epitopes to explain the molecular basis for alloantibody binding: toward predicting HLA antigenicity and immunogenicity, Transplantation, 99, 385, 10.1097/TP.0000000000000546 Mulder, 2005, Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies, J. Immunol., 175, 5950, 10.4049/jimmunol.175.9.5950 Duquesnoy, 2015, Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level?, Am. J. Transplant., 15, 923, 10.1111/ajt.13167 Duquesnoy, 2015, High-resolution HLA typing for sensitized patients: advances in medicine and science require us to challenge existing paradigms, Am. J. Transplant., 10.1111/ajt.13376 Doxiadis, 2009, Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both, Curr. Opin. Organ Transplant., 14, 410, 10.1097/MOT.0b013e32832c433f Abu Jawdeh, 2014, Desensitization in kidney transplantation: review and future perspectives, Clin. Transpl., 28, 494, 10.1111/ctr.12335 Montgomery, 2011, Desensitization in HLA-incompatible kidney recipients and survival, N. Engl. J. Med., 365, 318, 10.1056/NEJMoa1012376 Vo, 2008, Rituximab and intravenous immune globulin for desensitization during renal transplantation, N. Engl. J. Med., 359, 242, 10.1056/NEJMoa0707894 Woodle, 2015, Prospective iterative trial of proteasome inhibitor-based desensitization, Am. J. Transplant., 15, 101, 10.1111/ajt.13050 Riella, 2014, Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch, Transplantation, 97, 1247, 10.1097/01.TP.0000442782.98131.7c